Analysts/Institutional Investor Meet/Con. Call Updates

Shalby/SE/2026‐27/48 August 19, 2026 The Listing Department Corporate Service Department National Stock Exchange of India Ltd BSE Limited Mumbai 400 051. Mumbai 400 001. Scrip Code : SHALBY Scrip Code: 540797 Through : https://neaps.nseindia.com/NEWLISTINGCORP/ Through : http://listing.bseindia.com Sub.: Transcript of Earnings Conference Call for Q1 FY2027 Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 Dear Sir/Madam, Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith transcript of Earnings Conference Call held on August 13, 2026, wherein Unaudited Financial Results for Q1 FY 2026‐27 were discussed. The said transcript is also available in the Investors Section of our website. We request to take the same on your records. Thanking You, Yours faithfully, For Shalby Limited Tushar Shah Vice President & Company Secretary Mem. No: FCS‐7216 Encl.: Earnings call Transcript “Shalby Limited Q1 FY27 Earnings Conference Call” August 13, 2026 MANAGEMENT: DR. VIKRAM SHAH, CHAIRMAN AND MANAGING DIRECTOR MR. SHANAY SHAH, WHOLE-TIME DIRECTOR DR. NISHITA SHUKLA, CHIEF OPERATING OFFICER, SHALBY HOSPITALS MR. AMIT KUMAR –CHIEF FINANCIAL OFFICER, SHALBY LIMITED MR. DEEPAK ANAND – CHIEF EXECUTIVE OFFICER, SHALBY MEDTECH LIMITED MR. BABU THOMAS, CHIEF HUMAN RESOURCE OFFICER MR. JIGAR TODI – INVESTOR RELATIONS, SHALBY LIMITED MODERATOR: MR. KASHISH THAKUR – ELARA SECURITIES Page 1 of 11 Earnings Call Transcript Q1 FY27 August 13, 2026 Moderator: Ladies and gentlemen, good day and welcome to Q1 FY27 Earnings Conference Call of Shalby hosted by Elara Securities. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions at the end of the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing ‘*’ then ‘0’ on your touchtone phone. Please note that this conference is being recorded. I would now like to hand the conference over to Mr. Kashish Thakur from Elara Securities. Thank you and over to you, sir. Kashish Thakur: Thank you, Manav. Good morning, everyone. This is Kashish Thakur from Elara securities. We welcome all the participants to Shalby Limited Quarter 1 Financial Year 2027 Earnings Call hosted by Elara Securities. Today we have with us senior Management representatives from Shalby. We will start the call with performance highlights from Group CFO of Shalby Limited. – Mr. Amit Kumar and Mr. Deepak Anand – Chief Executive Officer of Shalby Medtech. After that, we will open the floor for question and answer for all the participants. I will now handover the call to Mr. Jigar Todi for important disclaimers regarding any forward- looking statement that may be made. Over to you, Jigar. Jigar Todi: Thanks, Kashish. Good morning, everyone. Our investor presentation is uploaded on the stock exchange website and our company website shalby.org. We do hope you have already had the opportunity to go through the presentation. Please note that some of the statements made in today's call may be forward looking in nature and may involve risks and uncertainties. Kindly refer to slide #2 of the investor presentation for a detailed disclaimer. Now, I would like to hand over the call to Group CFO – Mr. Amit Kumar for his opening remarks. Thank you and over to you, Amit. Amit Kumar: Thank you, Jigar. Good morning, everyone. Welcome to the earning call of Shalby limited for the Q1. Now, I will walk you through the consolidated financial performance of the company for the Quarter 1 of 2027. This performance I will explain in crores and on year-on-year basis: For the Quarter 1, the company delivered a healthy improvement across all key financial parameters starting with our consolidated revenues stood at ₹338.6 crores as against ₹303.4 crores in the Quarter 1 of the last year. This is with a strong growth of 11.6% on year-on-year basis. The EBITDA improved to ₹49 crores as against Quarter 1 of last year of ₹48.5 crores which is reflecting a growth of 1% on Y-on-Y basis. Our EBITDA margin stood at 14.5% compared to 16% in the corresponding quarter. Page 2 of 11 Earnings Call Transcript Q1 FY27 August 13, 2026 Consolidated PBT stood at ₹19.7 crores compared to ₹22.7 crores in the Quarter 1 of the last year with the PBT margin of 5.8%. The consolidated PAT has been higher at ₹10.5 crores with a PAT margin of 3.1% in the Q1 as against ₹7.7 crores with a PAT margin of 2.5% in the Quarter 1 of FY26. The group continues to maintain a healthy balance sheet with a comfortable gearing ratio of 0.46X and a net debt of approx. ₹463 crores. And we will further walk you through the standalone performance of the hospital segment: The standalone revenue for the Quarter 1 stood at ₹259 crores as against ₹242 crores in the Quarter 1 of the last year, registering a growth of approx. 7% on year-on-year basis. The standalone EBITDA approximately stood at ₹47.8 crores as against ₹52.4 crores in the Quarter 1 last year with an EBITDA margin of 18.4% versus 21.6% in the corresponding quarter last year. The standalone PBT stood at approx. ₹34 crores as against for approx. ₹40 crores in the Quarter 1 of the FY26 with a PBT margin of 13.1%. The standalone PAT stood at ₹25 crores compared to ₹25.7 crores in the Quarter 1 of the last year. This has a PAT margin of 9.7% in the Quarter 1 as against 10.6% in the Quarter 1 of the last year. At the net debt level, debt stands for the hospital segment for a ₹54.5 Cr at the end of the quarter. The standalone ROC for the quarter has been at 9.4% at an annualized level. The operationally ARPOB has been 44,711 compared to 45,673 in the corresponding quarter last year. The ALOS has stood at 3.69 days as compared to the Quarter 1 of the last year at 3.53 days. The number of occupied beds has increased to 701 in the Quarter 1 as against Quarter 1 of the last year at 639. This shows a growth of 9.8% year-on-year basis with an occupancy rate has been at 51% excluding Shalby International which stands at 54% during the quarter. The payer mix for the quarter had been 30% self-pay, 38% insurance and 32% government business. Importantly, now coming to Shalby International, our Gurgaon unit: The revenue stood at ₹26.2 crores as against quarter in the last year at ₹23.2 crores. Our ARPOB has also increased to 91,326 while ALOS has stood at 3.8 days during the quarter. International revenue contributed about 42% of the operating revenue of the Shalby International in the respective quarter. Importantly here we would like to mention that the Gurgaon unit has achieved its EBITDA break-even for the first time since the acquisition and this is a sustainable and a growing EBITDA we look forward in the subsequent quarter. Overall international business for the Shalby Group has been at about ₹13 Cr which comprises about ₹2 Cr coming from the Gurgaon unit and rest ₹11 crores coming from the other units of the Shalby hospitals. We are also pleased to share that during the quarter the group successfully completed 47 transplants including 41 kidney transplants, 5 liver transplants and 1 bone marrow transplant. This has been the summary of our hospital performance and the consolidated performance. Now from here I will move forward to our MedTech performance during the quarter at a consolidated and standalone level: Page 3 of 11 Earnings Call Transcript Q1 FY27 August 13, 2026 So, we have started FY27 on a very stronger note in our MedTech business with encouraging performance across our all key business units. Importantly a meaning and power improvement in our profitability. The first quarter demonstrates the progress we are making in building Shalby MedTech into a more diversified scalable and profitable medical technology platform. Also to brief you now, how the performance has been at the top line and EBITDA: To start with the top line and rev [Showing first 8,000 characters — download PDF for full document]